Chief Physician, Department of Thoracic Surgery, Peking University Cancer Hospital. Specialties: Peri‑operative comprehensive therapy for NSCLC and radical lung cancer resection following neoadjuvant therapy. He has conducted in‑depth research and accumulated extensive clinical experience in the whole‑process management of stage III‑IV lung cancer, surgical treatment of complex mediastinal tumors, and precise surgical resection of pulmonary metastatic tumors. Trained under a distinguished Chinese professor of thoracic surgery, he has long been engaged in clinical diagnosis, treatment and research of thoracic malignancies, boasting abundant surgical experience and multidisciplinary comprehensive management capabilities. He has carried out a great deal of pioneering work integrating neoadjuvant immunotherapy, targeted therapy and surgical strategies, and participated in multiple international multicenter clinical studies including CheckMate 816, Keynote‑671 and NeoAdaura, contributing to the standardization of neoadjuvant therapy for lung cancer in China. In terms of scientific research, his main focuses lie in the mechanisms of peri‑operative therapy for thoracic tumors, sensitivity prediction and the construction of prognostic models. In recent years, he has published numerous papers in top‑tier international oncology and thoracic surgery journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Journal of Thoracic and Cardiovascular Surgery, and Annals of Thoracic Surgery. He also took part in the National Key R&D Program project "Study on Molecular Characteristics and Mechanisms of Neoadjuvant Immunotherapy for Lung Cancer". He closely combines basic research with clinical practice and is committed to implementing precise treatment for thoracic tumors.